Studies on mice bearing P388 adriamycin sensitive and resistant lymphocytic leukemia were carried out to compare antitumor activity of adriamycin dissolved in Tween 80 (10 % in distilled water) with that of adriamycin dissolved in distilled water alone. The antitumor activity of adriamycin dissolved in acqueous solutions of Tween 80 was higher than that of adriamycin dissolved in distilled water against P388 leukemia sensitive to adriamycin. However, no change in the activity was observed in P388 leukemia resistant to adriamycin when the drug was administered either in acqueous solution of Tween 80 or in distilled water alone.
Get full access to this article
View all access options for this article.
References
1.
BasrurV.S., ChitnisM.P., MenonR.S.: Differential agglutination of P388 adriamycin sensitive and P388 adriamycin resistant leukaemia cells.Oncology, 40: 202–204, 1983.
2.
BiedlerJ.L., RiehmH.: Reduced cellular resistance to actinomycin-D in the presence of a detergent.Proc. Am. Assoc. Cancer Res., 10: 6, 1969.
3.
BowenD., GoldmanI.D.: The relationship among transport, intracellular binding and inhibition of RNA synthesis by actinomycin D in Ehrlich ascites tumour cells in vitro.Cancer Res., 35: 3054–3060, 1976.
4.
CarterS.K.: Adriamycin-a review J.Natl. Cancer Inst., 55: 1265–1274, 1975.
5.
ChervinskyD.S., WangJ.J.: Uptake of adriamycin and daunomycin in L1210 and human leukaemia cells: a comprehensive study.J. Med., 7: 63–79, 1976.
6.
ChitnisM.P., JohnsonR.K.: Biochemical parameters of resistance of an adriamycin-resistant subline of P388 leukaemia to emetine, an inhibitor of protein synthesis.J. Natl. Cancer Inst., 60: 1049–1054, 1978.
7.
DanoK.: Development of resistance to daunomycin (NSC-82151) in Ehrlich asictes tumour.Cancer Chemother. Rep., 55: 133–141, 1971.
8.
DanoK.: Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumour in vivo.Cancer Chemother. Rep., 56: 321–326, 1972.
9.
GeranR.J., GreenbergN.H., MacdonaldM.M., SchumacherA.M., AbbottB.J.: Protocols for screening chemical agents and natural products against animal tumours and other biological systems.Cancer Chemother. Rep., 3: 1–88, 1972.
10.
InabaM., JohnsonR.K.: Decreased retention of actinomycin-D as the basis for cross-resistance in anthracycline.Cancer Res., 37: 4629–4634, 1977.
11.
InabaM., JohnsonR.K.: Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline resistant subline of P388 leukaemia.Biochem. Pharmacol., 27: 2123–2130, 1978.
12.
InabaM., KabayashiH., SakuraiY., JohnsonR.K.: Active efflux of daunomycin and adriamycin in sensitive and resistant subline of P388 leukaemia.Cancer Res., 39: 2200–2203, 1979.
13.
JohnsonR.K., ChitnisM.P., GoldinA.: Characteristics of resistance and cross-resistance in vivo of subline of P388 leukaemia resistant to adriamycin.Pharmacologist., 18: 273, 1976.
14.
JohnsonR.K., ChitnisM.P., EmbreyW.M., GregoryB.E.: In vivo characteristics of resistance and cross-resistance of an adriamycin resistant subline of P388 leukaemia.Cancer Treat. Rep., 62: 1535–1547, 1978.
15.
KayE.R.M.: The effects of Tween 80 on the in vitro metabolism of cells of Ehrlich-Lettre ascites carcinoma.Cancer Res., 25: 764–768, 1965.
16.
KayE.R.M.: Effects of Tween 80 on the growth of Ehrlich-Lettre ascites carcinoma.Experientia, 21: 644–645, 1965.
17.
KlenerP., DonnerL., KozenaJ.: Daunorubicin and adriamycin in the treatment of leukaemia.Neoplasma20: 87–96, 1973.
18.
MenonR.S., ChitnisM.P., AdwankarM., BasrurV., AmonkarA.: Tween 80 alters natural resistance of Sarcoma 180 to bouvardin (NSC 259968).Tumori, 70: 23–27, 1984.
19.
PratesiG., CasazzaA.M., Di MarcoA.: Antitumour activity of N-trifluoroacetyladriamycin-14-Valerate.Cancer Treat. Rep., 62: 105–110, 1978.
20.
RiehmH., BiedlerJ.L.: Cellular resistance to daunomycin in Chinese hamster cells in vitro.Cancer Res., 31: 409–412, 1971.
21.
VecchiA., CairoM., MantovaniA., SironiM., SpreaficoF.: Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-Valerate.Cancer Treat. Rep., 62: 111–117, 1978.
